Click here to sign in with or

by Children's Hospital of Philadelphia

Researchers at Children's Hospital of Philadelphia (CHOP) have discovered a molecule that may have therapeutic benefits for children with a life-threatening form of mitochondrial disease. The findings were published in the journal JCI Insight.

Mitochondrial disease can describe a wide variety of conditions characterized by different symptoms and a range of severity. However, all of these conditions are linked by issues related to the mitochondria. Primary mitochondrial diseases are a growing class of genetic-based mitochondrial disorders, caused by inherited mutations in any of several hundred different genes.

One particularly severe form of primary mitochondrial disease is caused by variant in the F-Box and Leucine Rich Repeat Protein 4 (FBXL4) gene. At a microscopic level, this disorder disrupts the mitochondrial respiratory chain complex that converts oxygen and nutrients into energy, while also causing a buildup of lactic acid. The condition affects multiple systems in the body and can result in several symptoms including weakened muscle tone, slowed growth, developmental delays, impairment of motor skills and speech, seizures, and renal problems. Infants diagnosed with this disorder often only live into early to mid-childhood, prompting the need to investigate novel therapeutic interventions for these critically ill patients.

"These are typically very sick children. Since the gene that caused this form of mitochondrial disease was discovered by our research group a decade ago, we have been striving to find an intervention of true therapeutic value," said senior study author Marni Falk, MD, Professor of Pediatrics and Executive Director of the Mitochondrial Medicine Program at CHOP. "This study is truly the culmination of translating basic research into clinically relevant findings that represents an enormous breakthrough in understanding how we might be able to improve the health of these patients, along with the breadth of cellular effects that treatment may have."

In this study, researchers looked at 12 potential drug candidates and tested their effectiveness in newly created microscopic roundworm C. elegans models with FBXL4 gene pathogenic variants. Of these candidates, dichloroacetate (DCA) demonstrated clear beneficial effects on neuromotor activity and mitochondrial function. Validation studies were then performed both in zebrafish animal models and in human FBXL4 patient fibroblast cell lines, where DCA prevented stressor-induced brain death, impairment of neurologic and muscular functions, mitochondrial dysfunction, and other stressor-induced mitochondrial defects.

"We observed not only a reduction in tissue lactate levels but an improvement in mitochondria content when the FBXL4 disease models were treated with DCA," said Manuela Lavorato, Ph.D., a research assistant professor at the University of Pennsylvania School of Medicine and the Mitochondrial Medicine Frontier Program at CHOP and first author of the study. "With no other approved options, we believe our positive findings regarding DCA for the treatment of FBXL4 mitochondrial disease should lead to its rigorous clinical study in human patients." Explore further Lack of mitochondria causes severe disease in children More information: Manuela Lavorato et al, Dichloroacetate improves mitochondrial function, physiology, and morphology in FBXL4 disease models, JCI Insight (2022). DOI: 10.1172/jci.insight.156346 Journal information: JCI Insight

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

Daily science news on research developments and the latest scientific innovations

The latest engineering, electronics and technology advances

The most comprehensive sci-tech news coverage on the web

This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.